Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study

被引：2

作者：

Goebell, Peter J.

Kube, Ulrich

Staehler, Michael

Doehn, Christian

Steiner, Thomas

Kindler, Manfred

Herrmann, Edwin

Janssen, Jan

Weikert, Steffen

Scheffler, Michael Thomas

Schmitz, Joerg

Overkamp, Friedrich

Guderian, Gernot

Albrecht, Michael

Bergmann, Lothar

机构：

[1] Univ Erlangen Nurnberg, Dept Urol, D-91054 Erlangen, Germany

[2] Univ Munich, Dept Urol, Munich, Germany

[3] Urologikum Lubeck, Lubeck, Germany

[4] Helios Klinikum Erfurt, Urol Klin, Erfurt, Germany

[5] Univ Munster, Dept Urol, D-48149 Munster, Germany

[6] Charite Campus Mitte, Berlin, Germany

[7] Kliniken Stadt Koln Merheim, Cologne, Germany

[8] Praxis & Tagesklin Internist Onkol, Recklinghausen, Germany

[9] Novartis Pharma GmbH, Nurnberg, Germany

[10] Novartis Pharma GmbH, Dept Drug Safety & Epidemiol, Nurnberg, Germany

[11] Klinikum Johann Wolfgang Goethe Univ, Med Klin 3, Tumorzentrum Rhein Main, Frankfurt, Germany

来源：

关键词：

D O I：

10.1200/jco.2014.32.4_suppl.469

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

469

引用

页数：1